PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsSpinal muscular atrophy gene therapy coming to the NHS

BioNews

Spinal muscular atrophy gene therapy coming to the NHS

Published 11 March 2021 posted in News and appears in BioNews 1087

Author

Martha Roberts

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The NHS has agreed a deal to make gene therapy available for children with spinal muscular atrophy...

The NHS has agreed a deal to make gene therapy available for children with spinal muscular atrophy.

The treatment, called Zolgensma, has a list price of £1.79 million, but the NHS negotiated a deal with the manufacturer to secure the drug at a 'significant discount'.

'This deal is a life-changer for youngsters with this cruel disease and for their families,' said chief executive of NHS England Sir Simon Stevens, 'Spinal muscular atrophy is the leading genetic cause of death among babies and young children, which is why NHS England has moved mountains to make this treatment available.'

Spinal muscular atrophy (SMA) is a genetic condition that affects one in 6000 babies born. It is a disease of motor neurons, the nerve cells that control voluntary muscles used for movement. Due to faulty SMN1 genes, motor neurons lack a protein called SMN and progressively die. This leads to muscle wasting, causing difficulties with movement, and in severe forms of the disease with breathing and swallowing. 

The most aggressive type of SMA, type 1, affects children under six months old and leads to death or the need for permanent ventilation by two years of age. It is estimated that around 80 children per year could benefit from the new treatment.

Zolgensma contains a replica of the functional SMN1 gene which is delivered into the patient's cells by a harmless virus vector where it restores the SMN protein levels crucial for neuron and muscle function. The treatment only needs to be given once.

In clinical trials, children with both pre-symptomatic and symptomatic type 1 SMA were shown to benefit, with some children reaching life-changing milestones such as independent sitting and walking.

'The collaborative effort of all involved in the evaluation has made it possible to recommend a treatment which, at its list price, is the most expensive drug NICE has ever evaluated, allowing the lives of babies who might otherwise have died before their second birthday to be transformed,' said Meindert Boysen, deputy chief executive of the National Institute for Health and Care Excellence (NICE).

Sources and References

  • 08/03/2021
    NHS
    NHS England strikes deal on life-saving gene-therapy drug that can help babies with rare genetic disease move and walk
  • 08/03/2021
    BBC News
    Spinal muscular atrophy: Gene therapy approved by NHS
  • 08/03/2021
    National Institute for Health and Care Excellence
    NICE approves life-changing gene therapy for treating spinal muscular atrophy
  • 08/03/2021
    Pharma Times
    NHS England agrees deal with Novartis for access to SMA gene therapy Zolgensma

Related Articles

PET BioNews
Comment
29 November 2021 • 2 minutes read

FILM: Newborn Screening – What Should Be Screened for and How?

by BioNews

This film documents a Progress Educational Trust event about the screening of newborn babies for disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 June 2021 • 2 minutes read

Five-month-old baby receives £1.8 million gene therapy on the NHS

by Dr Molly Godfrey

A baby has become the first NHS patient to receive gene therapy for spinal muscular atrophy...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
25 February 2021 • 1 minute read

Stem cell treatment leads to improvement in spinal cord injuries

by Javier Bautista

Stem cell therapy significantly improved spinal cord injuries in a small clinical trial...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
26 August 2014 • 2 minutes read

Embryonic spinal cord precursor cells generated for first time

by Dr Lux Fatimathas

Scientists have generated the specialised cells in the embryo that go on to form spinal cord, muscle and bone tissue and used them to produce nerve and muscle cells...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Genetic therapy hope for muscle weakness disease

by Dr Jess Buxton

Boosting the activity of a gene could help treat people with an inherited muscle weakness disease, German researchers say. They have used a drug to help increase the levels of a crucial nerve protein missing in patients with spinal muscular atrophy (SMA). The team, based at...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« First study of the genomic architecture of the human placenta

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

4 July 2022 • 2 minutes read

Genetic and epigenetic causes of IVF embryo arrest discovered

4 July 2022 • 2 minutes read

Dutch donor-conceived people seek answers

4 July 2022 • 2 minutes read

Genetic variant increases Alzheimer's risk, especially in women

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856